Cited by 384HIV-related health complications and treatmentsLipoproteins and Cardiovascular HealthHIV/AIDS Research and Interventions

The DOI matches its Crossref record; 42 of the 43 references it cites were found in a registry or an index.

Predicting the risk of cardiovascular disease in HIV-infected patients: the Data collection on Adverse Effects of Anti-HIV Drugs Study

Open access

Friis-Møller, Nina, Thiébaut, Rodolphe, Reiss, Peter, Weber, Rainer, D'Arminio Monforte, Antonella, De Wit, Stephane, El-Sadr, Wafaa, Fontas, Eric, Worm, Signe, Kirk, Ole, Phillips, Andrew, Sabin, Caroline A., Lundgren, Jens D., Law, Matthew G., DAD study group·2010·European Journal of Cardiovascular Prevention & Rehabilitation

DOI 10.1097/hjr.0b013e328336a150

Open this paper in CoChat — free account

Abstract

AIMS: HIV-infected patients receiving combination antiretroviral therapy may experience metabolic complications, potentially increasing their risk of cardiovascular diseases (CVDs). Furthermore, exposures to some antiretroviral drugs seem to be independently associated with increased CVD risk. We aimed to develop cardiovascular risk-assessment models tailored to HIV-infected patients. METHODS AND RESULTS: Prospective multinational cohort study. The data set included 22,625 HIV-infected patients from 20 countries in Europe and Australia who were free of CVD at entry into the Data collection on Adverse Effects of Anti-HIV Drugs Study. Using cross-validation methods, separate models were developed to predict the risk of myocardial infarction, coronary heart disease, and a composite CVD endpoint. Model performance was compared with the Framingham score. The models included age, sex, systolic blood pressure, smoking status, family history of CVD, diabetes, total cholesterol, HDL cholesterol and indinavir, lopinavir/r and abacavir exposure. The models performed well with area under the receiver operator curve statistics of 0.783 (range 0.642-0.820) for myocardial infarction, 0.776 (0.670-0.818) for coronary heart disease and 0.769 (0.695-0.824) for CVD. The models estimated more accurately the outcomes in the subgroups than the Framingham score. CONCLUSION: Risk equations developed from a population of HIV-infected patients, incorporating routinely collected cardiovascular risk parameters and exposure to individual antiretroviral therapy drugs, might be more useful in estimating CVD risks in HIV-infected persons than conventional risk prediction models.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1097/hjr.0b013e328336a150

Cites

42 of 42 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study
Yusuf, S., Hawken, S., Ôunpuu, S., Dans, T., Avezum, A., Lanas, F., McQueen, M., Budaj, A., Pais, P., Varigos, J., et al. (2004) · The Lancet · doi:10.1016/s0140-6736(04)17018-9 · Cited by 12,026
Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies
(2002) · The Lancet · doi:10.1016/s0140-6736(02)11911-8 · Cited by 10,266
Blood cholesterol and vascular mortality by age, sex, and blood pressure: a meta-analysis of individual data from 61 prospective studies with 55,000 vascular deaths
(2007) · The Lancet · doi:10.1016/s0140-6736(07)61778-4 · Cited by 2,331
Myocardial infarction and coronary deaths in the World Health Organization MONICA Project. Registration procedures, event rates, and case-fatality rates in 38 populations from 21 countries in four continents.
Tunstall-Pedoe, H., Kuulasmaa, K., Amouyel, P., Arveiler, D., Rajakangas, A.-M., & Pająk, A. (1994) · Circulation · doi:10.1161/01.cir.90.1.583 · Cited by 2,260
CD4+ Count–Guided Interruption of Antiretroviral Treatment
The Strategies for Management of Antiretroviral Therapy (SMART) Study Group (2006) · New England Journal of Medicine · doi:10.1056/nejmoa062360 · Cited by 2,250
Cardiovascular disease risk profiles
Anderson, K. M., Odell, P. M., Wilson, P. W. F., & Kannel, W. B. (1991) · American Heart Journal · doi:10.1016/0002-8703(91)90861-b · Cited by 2,163
Validation of the Framingham Coronary Heart Disease Prediction Scores: Results of a Multiple Ethnic Groups Investigation
D'Agostino, R. B., Grundy, S., Sullivan, L. M., Wilson, P., & for the CHD Risk Prediction Group (2001) · JAMA · doi:10.1001/jama.286.2.180 · Cited by 2,108
Combination Antiretroviral Therapy and the Risk of Myocardial Infarction
El-Sadr, W. M., & The Data Collection On Adverse Events Of Anti-HIV Drugs (DAD) Study Group (2003) · New England Journal of Medicine · doi:10.1056/nejmoa030218 · Cited by 1,677
Self-citation
Increased acute myocardial infarction rates and cardiovascular risk factors among patients with human immunodeficiency virus disease
Triant, V. A., Lee, H., Hadigan, C., & Grinspoon, S. K. (2007) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2006-2190 · Cited by 1,613
Class of Antiretroviral Drugs and the Risk of Myocardial Infarction
(2007) · New England Journal of Medicine · doi:10.1056/nejmoa062744 · Cited by 1,521

Show all 43 references

Research works printed but not linked: 5

Lang S, 2009, Impact of specific NRTI and PI exposure on the risk of myocardial infarction: a case-control study nested within FHDH ANRS CO4
Benard A, 2006, Int J Tuberc Lung Dis, 10, 378
Patel N, 2006, Clin Occup Environ Med, 5, 193
Barrett-Connor EL, 1991, JAMA, 265, 627, 10.1001/jama.1991.03460050081025 · DOI
Friis-Moller N, 2007, Predicting the Risk of Coronary Heart Disease in HIV-infected Patients: The D:A:D Risk Equation

Sorted by citations

HIV Infection and the Risk of Acute Myocardial Infarction
Freiberg, M. S., Chang, C.-C. H., Kuller, L. H., Skanderson, M., Lowy, E., Kraemer, K. L., Butt, A. A., Goetz, M. B., Leaf, D. A., Oursler, K. A., et al. (2013) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2013.3728 · Cited by 1,340
Global Burden of Atherosclerotic Cardiovascular Disease in People Living With HIV: Systematic Review and Meta-Analysis
Shah, A. S. V., Stelzle, D., Lee, K. K., Beck, E. J., Alam, S., Clifford, S., Longenecker, C. T., Strachan, F., Bagchi, S., Whiteley, W., et al. (2018) · Circulation · doi:10.1161/circulationaha.117.033369 · Cited by 975
National Lipid Association Recommendations for Patient-Centered Management of Dyslipidemia: Part 2
Jacobson, T. A., Maki, K. C., Orringer, C. E., Jones, P. H., Kris-Etherton, P., Sikand, G., La Forge, R., Daniels, S. R., Wilson, D. P., Morris, P. B., et al. (2015) · Journal of Clinical Lipidology · doi:10.1016/j.jacl.2015.09.002 · Cited by 784
Characteristics, Prevention, and Management of Cardiovascular Disease in People Living With HIV: A Scientific Statement From the American Heart Association
Feinstein, M. J., Hsue, P. Y., Benjamin, L. A., Bloomfield, G. S., Currier, J. S., Freiberg, M. S., Grinspoon, S. K., Levin, J., Longenecker, C. T., & Post, W. S. (2019) · Circulation · doi:10.1161/cir.0000000000000695 · Cited by 673
HIV and Aging: State of Knowledge and Areas of Critical Need for Research. A Report to the NIH Office of AIDS Research by the HIV and Aging Working Group
High, K. P., Brennan-Ing, M., Clifford, D. B., Cohen, M. H., Currier, J., Deeks, S. G., Deren, S., Effros, R. B., Gebo, K., Goronzy, J. J., et al. (2012) · JAIDS Journal of Acquired Immune Deficiency Syndromes · doi:10.1097/qai.0b013e31825a3668 · Cited by 522
Bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir, abacavir, and lamivudine for initial treatment of HIV-1 infection (GS-US-380-1489): a double-blind, multicentre, phase 3, randomised controlled non-inferiority trial
Gallant, J. E., Lazzarin, A., Mills, A., Orkin, C. M., Podzamczer, D., Tebas, P., Girard, P., Brar, I., Daar, E. S., Wohl, D. A., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(17)32299-7 · Cited by 394
Patterns of Cardiovascular Mortality for HIV-Infected Adults in the United States: 1999 to 2013
Feinstein, M. J., Bahiru, E. M., Achenbach, C. J., Longenecker, C. T., Hsue, P. Y., So‐Armah, K., Freiberg, M. S., & Lloyd‐Jones, D. M. (2015) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2015.10.030 · Cited by 300
HIV and Coronary Heart Disease
Boccara, F., Lang, S., Meuleman, C., Éderhy, S., Mary‐Krause, M., Costagliola, D. G., Capeau, J., & Cohen, A. A. (2013) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2012.06.063 · Cited by 261
HIV infection and cardiovascular disease
Hemkens, L. G., & Bucher, H. C. (2014) · European Heart Journal · doi:10.1093/eurheartj/eht528 · Cited by 251
An updated prediction model of the global risk of cardiovascular disease in HIV-positive persons: The Data-collection on Adverse Effects of Anti-HIV Drugs (D:A:D) study
Friis‐Møller, N., Ryom, L., Smith, C. J., Weber, R. K., Reiss, P., Dabis, F., Wit, S. D., Monforte, A. D., Kirk, O., Fontas, É., et al. (2015) · European Journal of Preventive Cardiology · doi:10.1177/2047487315579291 · Cited by 242
Self-citation
Cardiovascular Risk Prediction Functions Underestimate Risk in HIV Infection
Triant, V. A., Perez, J., Regan, S., Massaro, J. M., Meigs, J. B., Grinspoon, S. K., & D’Agostino, R. B. (2018) · Circulation · doi:10.1161/circulationaha.117.028975 · Cited by 237
Cardiovascular Disease and HIV Infection
Triant, V. A. (2013) · Current HIV/AIDS Reports · doi:10.1007/s11904-013-0168-6 · Cited by 236
B ritish HIV A ssociation guidelines for the routine investigation and monitoring of adult HIV ‐1‐infected individuals 2011
Asboe, D., Aitken, C., Boffito, M., Booth, C. L., Cane, P., Fakoya, A. O., Geretti, A. M., Kelleher, P., Mackie, N., Muir, D., et al. (2011) · HIV Medicine · doi:10.1111/j.1468-1293.2011.00971.x · Cited by 197
Self-citation
HIV Infection and Cardiovascular Disease
Fuchs, S. C. P. C., Moreira, M. B., Oyeledun, B., Sow, P. S., & Vitória, M. (2013) · The Scientific World JOURNAL · doi:10.1155/2013/252463 · Cited by 191
Rates of cardiovascular disease following smoking cessation in patients with HIV infection: results from the D:A:D study*
Petoumenos, K., Worm, S. W., Reiss, P., Wit, S. D., Monforte, A. D., Sabin, C. A., Friis‐Møller, N., Weber, R. K., Mercié, P., Pradier, C., et al. (2011) · HIV Medicine · doi:10.1111/j.1468-1293.2010.00901.x · Cited by 189
Self-citation
Short‐term weight gain after antiretroviral therapy initiation and subsequent risk of cardiovascular disease and diabetes: the D : A : D study
Achhra, A. C., Mocroft, A., Reiss, P., Sabin, C. A., Ryom, L., Wit, S. D., Smith, C. J., Monforte, A. D., Phillips, A. N., Weber, R. K., et al. (2015) · HIV Medicine · doi:10.1111/hiv.12294 · Cited by 163
Self-citation
HIV Replication and Immune Status Are Independent Predictors of the Risk of Myocardial Infarction in HIV-Infected Individuals
Lang, S., Mary‐Krause, M., Simon, A., Partisani, M., Gilquin, J., Cotte, L., Boccara, F., & Costagliola, D. G. (2012) · Clinical Infectious Diseases · doi:10.1093/cid/cis489 · Cited by 159
Aspirin Attenuates Platelet Activation and Immune Activation in HIV-1-Infected Subjects on Antiretroviral Therapy
O’Brien, M. P., Montenont, E., Hu, L., Nardi, M. A., Valdes, V., Merolla, M., Gettenberg, G., Cavanagh, K., Aberg, J. A., Bhardwaj, N., et al. (2013) · JAIDS Journal of Acquired Immune Deficiency Syndromes · doi:10.1097/qai.0b013e31828a292c · Cited by 146
Cardiovascular Disease Risk Prediction in the HIV Outpatient Study
Thompson‐Paul, A. M., Lichtenstein, K. A., Armon, C., Palella, F. J., Skarbinski, J., Chmiel, J. S., Hart, R. L. D., Wei, S. C., Loustalot, F. V., Brooks, J. T., et al. (2016) · Clinical Infectious Diseases · doi:10.1093/cid/ciw615 · Cited by 141
Metabolic syndrome in HIV-infected individuals: underlying mechanisms and epidemiological aspects
de Paula, A. A., Falcão, M., & Pacheco, A. G. (2013) · AIDS Research and Therapy · doi:10.1186/1742-6405-10-32 · Cited by 132
British HIV Association guidelines for the treatment of HIV ‐1‐positive adults with antiretroviral therapy 2015
Churchill, D. R., Waters, L. J., Ahmed, N., Angus, B., Boffito, M., Bower, M., Dunn, D. T., Edwards, S., Emerson, C., Fidler, S. J., et al. (2016) · HIV Medicine · doi:10.1111/hiv.12426 · Cited by 133
Self-citation
Aging and the evolution of comorbidities among HIV-positive individuals in a European cohort
Pelchen–Matthews, A., Ryom, L., Borges, Á. H., Edwards, S., Duvivier, C., Stephan, C., Sambatakou, H., Maciejewska, K., Portu, J. J., Weber, J. N., et al. (2018) · AIDS · doi:10.1097/qad.0000000000001967 · Cited by 125
Self-citation
Prehypertension, Hypertension, and the Risk of Acute Myocardial Infarction in HIV-Infected and -Uninfected Veterans
So‐Armah, K., Chang, C. H., Baker, J. V., Vasan, R. S., Budoff, M. J., Crane, H. M., Gibert, C. L., Goetz, M. B., Leaf, D. A., McGinnis, K. A., et al. (2013) · Clinical Infectious Diseases · doi:10.1093/cid/cit652 · Cited by 121
Is there continued evidence for an association between abacavir usage and myocardial infarction risk in individuals with HIV? A cohort collaboration
for the D:A:D Study Group, Sabin, C. A., Reiss, P., Ryom, L., Phillips, A. N., Weber, R. K., Law, M. G., Fontas, É., Mocroft, A., Wit, S. D., et al. (2016) · BMC Medicine · doi:10.1186/s12916-016-0588-4 · Cited by 119
Self-citation
Association of Macrophage Inflammation Biomarkers With Progression of Subclinical Carotid Artery Atherosclerosis in HIV-Infected Women and Men
Hanna, D. B., Lin, J., Post, W. S., Hodis, H. N., Xue, X., Anastos, K., Cohen, M. H., Gange, S. J., Haberlen, S., Heath, S. L., et al. (2017) · The Journal of Infectious Diseases · doi:10.1093/infdis/jix082 · Cited by 113
HIV, Vascular and Aging Injuries in the Brain of Clinically Stable HIV-Infected Adults: A 1H MRS Study
Cysique, L. A., Moffat, K., Moore, D. M., Lane, T. A., Davies, N. W. S., Carr, A. D., Brew, B. J., & Rae, C. D. (2013) · PLoS ONE · doi:10.1371/journal.pone.0061738 · Cited by 105
Risk of coronary heart disease in patients with HIV infection
Zanni, M. V., Schouten, J., Grinspoon, S. K., & Reiss, P. (2014) · Nature Reviews Cardiology · doi:10.1038/nrcardio.2014.167 · Cited by 107
Self-citation
Metabolic syndrome, diabetes, and cardiovascular risk in HIV
Nix, L. M., & Tien, P. C. (2014) · Current HIV/AIDS Reports · doi:10.1007/s11904-014-0219-7 · Cited by 96
Bictegravir versus dolutegravir, each with emtricitabine and tenofovir alafenamide, for initial treatment of HIV-1 infection: a randomised, double-blind, phase 2 trial
Sax, P. E., DeJesus, E., Crofoot, G. E., Ward, D. J., Benson, P. M., Dretler, R. H., Mills, A., Brinson, C. C., Péloquin, J., Wei, X., et al. (2017) · The Lancet HIV · doi:10.1016/s2352-3018(17)30016-4 · Cited by 95
High Prevalence of Metabolic Syndrome and Cardiovascular Disease Risk Among People with HIV on Stable ART in Southwestern Uganda
Muyanja, D. M., Muzoora, C. K., Muyingo, A., Muyindike, W. R., & Siedner, M. J. (2015) · AIDS Patient Care and STDs · doi:10.1089/apc.2015.0213 · Cited by 94
Antiviral Activity, Safety, and Pharmacokinetics of Bictegravir as 10-Day Monotherapy in HIV-1–Infected Adults
Gallant, J. E., Thompson, M., DeJesus, E., Voskuhl, G. W., Wei, X., Zhang, H., White, K., Cheng, A., Quirk, E. K., & Martin, H. (2017) · JAIDS Journal of Acquired Immune Deficiency Syndromes · doi:10.1097/qai.0000000000001306 · Cited by 94
Lipid profile of HIV-infected patients in relation to antiretroviral therapy: a review
Souza, S. J., Luzia, L. A., dos Santos, S. D. S., & Rondó, P. H. D. C. (2013) · Revista da Associação Médica Brasileira · doi:10.1016/j.ramb.2012.11.003 · Cited by 93
Dyslipidemia related to antiretroviral therapy.
Estrada, E., & Portilla, J. (2011) · PubMed · Cited by 89
The Burden of Diabetes and Hyperlipidemia in Treated HIV Infection and Approaches for Cardiometabolic Care
Samaras, K. (2012) · Current HIV/AIDS Reports · doi:10.1007/s11904-012-0124-x · Cited by 89
Are HIV patients undertreated? Cardiovascular risk factors in HIV: results of the HIV-HEART study
Reinsch, N., Neuhaus, K., Eßer, S., Potthoff, A. V., Hower, M., Mostardt, S., Neumann, A., Brockmeyer, N. H., Gelbrich, G., Erbel, R., et al. (2011) · European Journal of Preventive Cardiology · doi:10.1177/1741826711398431 · Cited by 85
Vascular cognitive impairment and HIV-associated neurocognitive disorder: a new paradigm
Cysique, L. A., & Brew, B. J. (2019) · Journal of NeuroVirology · doi:10.1007/s13365-018-0706-5 · Cited by 85
Effect of Cumulating Exposure to Abacavir on the Risk of Cardiovascular Disease Events in Patients From the Swiss HIV Cohort Study
Young, J., Xiao, Y., Moodie, E. E. M., Abrahamowicz, M., Klein, M. B., Bernasconi, E., Schmid, P., Calmy, A., Cavassini, M. L., Cusini, A., et al. (2015) · JAIDS Journal of Acquired Immune Deficiency Syndromes · doi:10.1097/qai.0000000000000662 · Cited by 83
Self-citation
Inflammatory Co-morbidities in HIV+ Individuals: Learning Lessons from Healthy Ageing
Hearps, A. C., Martin, G. E., Rajasuriar, R., & Crowe, S. M. (2014) · Current HIV/AIDS Reports · doi:10.1007/s11904-013-0190-8 · Cited by 84
Novel Biomarkers of Cardiac Stress, Cardiovascular Dysfunction, and Outcomes in HIV-Infected Individuals
Secemsky, E. A., Scherzer, R., Nitta, E. M., Wu, A. H. B., Lange, D. C., Deeks, S. G., Martin, J. N., Snider, J., Ganz, P., & Hsue, P. Y. (2015) · JACC Heart Failure · doi:10.1016/j.jchf.2015.03.007 · Cited by 80
HIV-associated neurocognitive disorder in Australia: a case of a high-functioning and optimally treated cohort and implications for international neuroHIV research
Cysique, L. A., Heaton, R. K., Kamminga, J., Lane, T. A., Gates, T. M., Moore, D. M., Hubner, E., Carr, A. D., & Brew, B. J. (2014) · Journal of NeuroVirology · doi:10.1007/s13365-014-0242-x · Cited by 73
Contribution of Genetic Background, Traditional Risk Factors, and HIV-Related Factors to Coronary Artery Disease Events in HIV-Positive Persons
Rotger, M., Glass, T. R., Junier, T., Lundgren, J. D., Neaton, J. D., Poloni, E. S., Wout, A. B. V. ’., Lubomirov, R., Colombo, S. F., Martínez, R., et al. (2013) · Clinical Infectious Diseases · doi:10.1093/cid/cit196 · Cited by 76
Self-citation
Serious Non-AIDS events: Immunopathogenesis and interventional strategies
Hsu, D. C., Sereti, I., & Ananworanich, J. (2013) · AIDS Research and Therapy · doi:10.1186/1742-6405-10-29 · Cited by 73
Changes in Cardiovascular Disease Risk Factors With Immediate Versus Deferred Antiretroviral Therapy Initiation Among HIV‐Positive Participants in the START (Strategic Timing of Antiretroviral Treatment) Trial
Baker, J. V., Sharma, S., Achhra, A. C., Bernardino, J. I., Bogner, J. R., Duprez, D. A., Emery, S., Gazzard, B., Gordin, J. S., Grandits, G., et al. (2017) · Journal of the American Heart Association · doi:10.1161/jaha.116.004987 · Cited by 74
Self-citation
Underutilization of Aspirin for Primary Prevention of Cardiovascular Disease Among HIV-Infected Patients
Burkholder, G., Tamhane, A. R., Salinas, J. L., Mugavero, M. J., Raper, J. L., Westfall, A. O., Saag, M. S., & Willig, J. H. (2012) · Clinical Infectious Diseases · doi:10.1093/cid/cis752 · Cited by 73
Incidence of dyslipidemia in people with HIV who are treated with integrase inhibitors versus other antiretroviral agents
The RESPOND Study Group∗ (2021) · AIDS · doi:10.1097/qad.0000000000002811 · Cited by 73
Management of the metabolic effects of HIV and HIV drugs
Brown, T. T., & Glesby, M. J. (2011) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2011.151 · Cited by 73
Regional fat deposition and cardiovascular risk in HIV infection: the FRAM study
Lake, J. E., Wohl, D. A., Scherzer, R., Grünfeld, C., Tien, P. C., Sidney, S., & Currier, J. S. (2011) · AIDS Care · doi:10.1080/09540121.2010.543885 · Cited by 71
Cardiovascular Risk Estimation in 2012: Lessons Learned and Applicability to the HIV Population
D’Agostino, R. B. (2012) · The Journal of Infectious Diseases · doi:10.1093/infdis/jis196 · Cited by 71
Predicting the short‐term risk of diabetes in HIV‐positive patients: the Data Collection on Adverse Events of Anti‐HIV Drugs (D:A:D) study
Petoumenos, K., Worm, S. W., Fontas, É., Weber, R. K., Wit, S. D., Bruyand, M., Reiss, P., El-Sadr, W. M., Monforte, A. D., Friis‐Møller, N., et al. (2012) · Journal of the International AIDS Society · doi:10.7448/ias.15.2.17426 · Cited by 70
Self-citation
Pharmacokinetics and Pharmacodynamics of Antiretrovirals in the Central Nervous System
Calcagno, A., Perri, G. D., & Bonora, S. (2014) · Clinical Pharmacokinetics · doi:10.1007/s40262-014-0171-0 · Cited by 73
Prevalence of cardiovascular diseases in HIV-infected outpatients: results from a prospective, multicenter cohort study
Eßer, S., Gelbrich, G., Brockmeyer, N. H., Goehler, A., Schadendorf, D., Erbel, R., Neumann, T., & Reinsch, N. (2012) · Clinical Research in Cardiology · doi:10.1007/s00392-012-0519-0 · Cited by 69
Risk of Cardiovascular Disease in an Aging HIV Population: Where Are We Now?
Martín-Iguacel, R., Llibre, J. M., & Friis‐Møller, N. (2015) · Current HIV/AIDS Reports · doi:10.1007/s11904-015-0284-6 · Cited by 69
Self-citation
Assessing Cardiovascular Risk in People Living with HIV: Current Tools and Limitations
Achhra, A. C., Lyass, A., Borowsky, L. H., Bogorodskaya, M., Plutzky, J., Massaro, J. M., D’Agostino, R. B., & Triant, V. A. (2021) · Current HIV/AIDS Reports · doi:10.1007/s11904-021-00567-w · Cited by 65
Cardiovascular disease in patients with HIV
Ballocca, F., D’Ascenzo, F., Gili, S., Marra, W. G., & Gaïta, F. (2017) · Trends in Cardiovascular Medicine · doi:10.1016/j.tcm.2017.06.005 · Cited by 64
Cardiovascular risk prediction in HIV ‐infected patients: comparing the Framingham, atherosclerotic cardiovascular disease risk score ( ASCVD ), Systematic Coronary Risk Evaluation for the N etherlands (SCORE ‐ NL) and Data Collection on Adverse Events of Anti‐ HIV Drugs ( D : A : D ) risk prediction models
Krikke, M., Hoogeveen, R., Hoepelman, A. I. M., Visseren, F. L. J., & Arends, J. (2015) · HIV Medicine · doi:10.1111/hiv.12300 · Cited by 63
Assessment of cardiovascular risk factors in people with HIV infection treated with ART in rural South Africa: a cross sectional study
Mashinya, F., Alberts, M., Geertruyden, J. V., & Colebunders, R. (2015) · AIDS Research and Therapy · doi:10.1186/s12981-015-0083-6 · Cited by 62
Cardiovascular Risk Assessment: A Comparison of the Framingham, PROCAM, and DAD Equations in HIV‐Infected Persons
Nery, M. W., Martelli, C. M. T., Silveira, É. A., de Sousa, C. A., Falco, M. D. O., Castro, A. D. C. O., Esper, J. T., Souza, L. C. S. E., & Turchi, M. D. (2013) · The Scientific World JOURNAL · doi:10.1155/2013/969281 · Cited by 62
Performance of Cardiovascular Risk Prediction Models Among People Living With HIV
Soares, C., Kwok, M. J., Boucher, K.-A., Haji, M. S., Echouffo-Tcheugui, J. B., Longenecker, C. T., Bloomfield, G. S., Ross, D. A., Jutkowtiz, E., Sullivan, J. L., et al. (2022) · JAMA Cardiology · doi:10.1001/jamacardio.2022.4873 · Cited by 57
HIV Infection and Primary Prevention of Cardiovascular Disease: Lights and Shadows in the HAART Era
Ballocca, F., Gili, S., D’Ascenzo, F., Marra, W. G., Cannillo, M., Calcagno, A., Bonora, S., Flammer, A. J., Coppola, J., Moretti, C., et al. (2016) · Progress in Cardiovascular Diseases · doi:10.1016/j.pcad.2016.02.008 · Cited by 56
Reversible effect on lipids by switching from tenofovir disoproxil fumarate to tenofovir alafenamide and back
Milinkovic, A., Berger, F., Arenas‐Pinto, A., & Mauss, S. (2019) · AIDS · doi:10.1097/qad.0000000000002350 · Cited by 55
Factors Associated With Excess Myocardial Infarction Risk in HIV-Infected Adults: A Systematic Review and Meta-analysis
Rao, S. G., Galaviz, K. I., Gay, H. C., Wei, J., Armstrong, W. S., del Rı́o, C., Narayan, K. M. V., & Ali, M. K. (2019) · JAIDS Journal of Acquired Immune Deficiency Syndromes · doi:10.1097/qai.0000000000001996 · Cited by 55
Coronary Artery Calcification in Hemophilia A
Tuinenburg, A., Rutten, A., Kavousi, M., Leebeek, F. W. G., Ypma, P. F., Gorkom, B. A. P. L., Nijziel, M. R., Kamphuisen, P. W., Mauser‐Bunschoten, E. P., Roosendaal, G., et al. (2011) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.111.238162 · Cited by 54
Cardiovascular risk assessment in persons with HIV infection in the developing world: comparing three risk equations in a cohort of HIV-infected Thais: Cardiovascular risk in HIV-infected Thais
Edwards-Jackson, N., Kerr, S., Tieu, H., Ananworanich, J., Hammer, S., Ruxrungtham, K., Phanuphak, P., Avihingsanon, A., & for the HIV-NAT 006 Study Team (2011) · HIV Medicine · doi:10.1111/j.1468-1293.2011.00916.x · Cited by 53
Dyslipidemia and Cardiovascular Risk in Human Immunodeficiency Virus Infection
Kelesidis, T., & Currier, J. S. (2014) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2014.06.003 · Cited by 53
Aggregate Risk of Cardiovascular Disease Among Adolescents Perinatally Infected With the Human Immunodeficiency Virus
Patel, K., Wang, J., Jacobson, D. L., Lipshultz, S. E., Landy, D. C., Geffner, M. E., DiMeglio, L. A., Seage, G. R., Williams, P. L., Dyke, R. B. V., et al. (2013) · Circulation · doi:10.1161/circulationaha.113.001978 · Cited by 52
Increased risk of cardiovascular disease ( CVD ) with age in HIV ‐positive men: a comparison of the D : A : D CVD risk equation and general population CVD risk equations
Petoumenos, K., Reiss, P., Ryom, L., Rickenbach, M., Sabin, C. A., El‐Sadr, W., Monforte, A. D., Phillips, A. N., Wit, S. D., Kirk, O., et al. (2014) · HIV Medicine · doi:10.1111/hiv.12162 · Cited by 56
Self-citation
Prevalence, Treatment, and Control of Dyslipidemia and Hypertension in 4278 HIV Outpatients
Myerson, M. L., Poltavskiy, E. A., Armstrong, E. J., Kim, S., Sharp, V. J. A., & Bang, H. (2014) · JAIDS Journal of Acquired Immune Deficiency Syndromes · doi:10.1097/qai.0000000000000168 · Cited by 50
Human Immunodeficiency Virus as a Chronic Disease: Evaluation and Management of Nonacquired Immune Deficiency Syndrome-Defining Conditions
Villar, S. S., Gutiérrez, F., Miralles, C., Berenguer, J., Rivero, A., Martínez, E., & Moreno, S. (2016) · Open Forum Infectious Diseases · doi:10.1093/ofid/ofw097 · Cited by 53
Myocardial Fibrosis and Inflammation by CMR Predict Cardiovascular Outcome in People Living With HIV
de Leuw, P., Arendt, C. T., Haberl, A. E., Froadinadl, D., Kann, G., Wolf, T., Stephan, C., Schüttfort, G., Vásquez, M., Arcari, L., et al. (2021) · JACC. Cardiovascular imaging · doi:10.1016/j.jcmg.2021.01.042 · Cited by 50
Comparative safety and efficacy of statins for primary prevention in human immunodeficiency virus-positive patients: a systematic review and meta-analysis
Gili, S., Marra, W. G., D’Ascenzo, F., Lonni, E., Calcagno, A., Cannillo, M., Ballocca, F., Cerrato, E., Pianelli, M., Barbero, U., et al. (2016) · European Heart Journal · doi:10.1093/eurheartj/ehv734 · Cited by 49
Atherosclerotic Cardiovascular Disease Risk Profile of Tenofovir Alafenamide Versus Tenofovir Disoproxil Fumarate
Huhn, G. D., Shamblaw, D., Baril, J.-G., Hsue, P. Y., Mills, B. L., Nguyen-Cleary, T., McCallister, S. H., & Das, M. (2019) · Open Forum Infectious Diseases · doi:10.1093/ofid/ofz472 · Cited by 51
Platelet Transcriptome Profiling in HIV and ATP-Binding Cassette Subfamily C Member 4 (ABCC4) as a Mediator of Platelet Activity
Marcantoni, E., Allen, N., Cambria, M. R., Dann, R. B., Cammer, M., Lhakhang, T. W., O’Brien, M. P., Kim, B. B., Worgall, T. S., Heguy, A., et al. (2018) · JACC Basic to Translational Science · doi:10.1016/j.jacbts.2017.10.005 · Cited by 50
Cardiovascular disease in human immunodeficiency virus infected patients: A true or perceived risk?
Shahbaz, S. (2015) · World Journal of Cardiology · doi:10.4330/wjc.v7.i10.633 · Cited by 47
Long-term predictive value of the Framingham Risk Score for Stroke in HIV-positive vs HIV-negative men
Mateen, F. J., Post, W. S., Sacktor, N. C., Abraham, A. G., Becker, J. T., Smith, B., Detels, R., Martin, E. M., Phair, J., & Shinohara, R. T. (2013) · Neurology · doi:10.1212/01.wnl.0000437296.97946.73 · Cited by 47
Antiretroviral therapy related adverse effects: Can sub-Saharan Africa cope with the new “test and treat” policy of the World Health Organization?
Nansseu, J. R., & Bigna, J. J. (2017) · Infectious Diseases of Poverty · doi:10.1186/s40249-017-0240-3 · Cited by 47
Extrahepatic Manifestations of Hepatitis C Infection: Navigating CHASM
Sherman, A. C., & Sherman, K. E. (2015) · Current HIV/AIDS Reports · doi:10.1007/s11904-015-0274-8 · Cited by 47
Coronary Artery Calcification and Plaque Characteristics in People Living With HIV: A Systematic Review and Meta‐Analysis
Soares, C., Samara, A., Yuyun, M. F., Echouffo-Tcheugui, J. B., Masri, A., Samara, A., Morrison, A., Lin, N., Wu, W., & Erqou, S. A. (2021) · Journal of the American Heart Association · doi:10.1161/jaha.120.019291 · Cited by 47
Cardiovascular disease risk in an aging HIV population: not just a question of biology
So-Armah, K., & Freiberg, M. S. (2014) · Current Opinion in HIV and AIDS · doi:10.1097/coh.0000000000000065 · Cited by 45
Ideal Cardiovascular Health and Carotid Atherosclerosis in a Mixed Cohort of HIV-Infected and Uninfected Ugandans
Feinstein, M. J., Kim, J., Bibangambah, P., Sentongo, R. N., Martin, J. N., Tsai, A. C., Bangsberg, D. R., Hemphill, L., Triant, V. A., Boum, Y., et al. (2016) · AIDS Research and Human Retroviruses · doi:10.1089/aid.2016.0104 · Cited by 45
Management of lipid disorders in patients living with HIV
Myerson, M. L., Malvestutto, C., & Aberg, J. A. (2015) · The Journal of Clinical Pharmacology · doi:10.1002/jcph.473 · Cited by 44
HIV , highly active antiretroviral therapy and the heart: a cellular to epidemiological review
Lambert, C., Sandesara, P. B., Hirsh, B. J., Shaw, L. J., Lewis, W., Quyyumi, A. A., Schinazi, R., Post, W. S., & Sperling, L. S. (2015) · HIV Medicine · doi:10.1111/hiv.12346 · Cited by 44
Epidemiology of ischemic heart disease in HIV
Triant, V. A., & Grinspoon, S. K. (2017) · Current Opinion in HIV and AIDS · doi:10.1097/coh.0000000000000410 · Cited by 44
Cardiovascular risk factors in HIV infected individuals: Comparison with general adult control population in Greece
Touloumi, G., Kalpourtzi, N., Papastamopoulos, V., Paparizos, V., Adamis, G., Antoniadou, A., Chini, M., Karakosta, A., Makrilakis, K., Gavana, M., et al. (2020) · PLoS ONE · doi:10.1371/journal.pone.0230730 · Cited by 45
Cardiovascular risk assessment in people living with HIV compared to the general population
Delabays, B., Cavassini, M. L., Damas, J., Beuret, H., Calmy, A., Hasse, B. K., Bucher, H. C., Frischknecht, M., Müller, O., Méan, M., et al. (2021) · European Journal of Preventive Cardiology · doi:10.1093/eurjpc/zwab201 · Cited by 43
Clinical management of dyslipidaemia associated with combination antiretroviral therapy in HIV-infected patients
Calza, L., Colangeli, V., Manfredi, R., Bon, I., Re, M. C., & Viale, P. (2016) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkv494 · Cited by 42
The Additive Value of Femoral Ultrasound for Subclinical Atherosclerosis Assessment in a Single Center Cohort of 962 Adults, Including High Risk Patients with Rheumatoid Arthritis, Human Immunodeficiency Virus Infection and Type 2 Diabetes Mellitus
Protogerou, A. D., Fransen, J., Zampeli, E., Argyris, A., Aissopou, E., Arida, A., Konstantonis, G. D., Tentolouris, N., Makrilakis, K., Psichοgiou, M., et al. (2015) · PLoS ONE · doi:10.1371/journal.pone.0132307 · Cited by 41
Persistently Elevated Serum Interleukin-6 Predicts Mortality Among Adults Receiving Combination Antiretroviral Therapy in Botswana: Results from a Clinical Trial
McDonald, B., Moyo, S. M., Gabaitiri, L., Gaseitsiwe, S., Bussmann, H., Koethe, J. R., Musonda, R. M., Makhema, J. M., Novitsky, V., Marlink, R., et al. (2013) · AIDS Research and Human Retroviruses · doi:10.1089/aid.2012.0309 · Cited by 41
Evolution of comorbidities in people living with HIV between 2004 and 2014: cross-sectional analyses from ANRS CO3 Aquitaine cohort
Bonnet, F., Marec, F. L., Leleux, O., Gerard, Y., Neau, D., Lazaro, E., Duffau, P., Caubet, O., Vandenhende, M. A., Mercié, P., et al. (2020) · BMC Infectious Diseases · doi:10.1186/s12879-020-05593-4 · Cited by 41
Plasma Efavirenz Concentrations Are Associated With Lipid and Glucose Concentrations
Sinxadi, P., McIlleron, H., Dave, J. A., Smith, P. J., Levitt, N. S., Haas, D. W., & Maartens, G. (2016) · Medicine · doi:10.1097/md.0000000000002385 · Cited by 42
Management of metabolic complications and cardiovascular risk in HIV-infected patients.
Blanco, F., Román, J. S., Vispo, E., López, M., Salto, A., Abad, V., & Soriano, V. (2010) · PubMed · Cited by 40
Nutrition and the HIV-associated lipodystrophy syndrome
Loonam, C., & Mullen, A. (2012) · Nutrition Research Reviews · doi:10.1017/s0954422411000138 · Cited by 40
What happens to cardiovascular system behind the undetectable level of HIV viremia?
d’Ettorre, G., Ceccarelli, G., Pavone, P., Vittozzi, P., Girolamo, G. D., Schietroma, I., Serafino, S., Giustini, N., & Vullo, V. (2016) · AIDS Research and Therapy · doi:10.1186/s12981-016-0105-z · Cited by 41
Enhanced Effector Function of CD8+ T Cells From Healthy Controls and HIV-Infected Patients Occurs Through Thrombin Activation of Protease-Activated Receptor 1
Hurley, A., Smith, M., Karpova, T., Hasley, R. B., Belkina, N., Shaw, S. M., Balenga, N. A. B., Druey, K. M., Nickel, E., Packard, B. Z., et al. (2012) · The Journal of Infectious Diseases · doi:10.1093/infdis/jis730 · Cited by 40
Antihypertensive Drugs in Patients Treated with Antiretroviral
Peyrière, H., Eiden, C., Macia, J., & Reynes, J. (2012) · Annals of Pharmacotherapy · doi:10.1345/aph.1q546 · Cited by 39
Metabolic Syndrome Among Antiretroviral Therapy-Naive Versus Experienced HIV-Infected Patients Without Preexisting Cardiometabolic Disorders in Western Kenya
Osoti, A. O., Temu, T. M., Kirui, N., Ngetich, E. K., Kamano, J. H., Page, S. T., Farquhar, C., & Bloomfield, G. S. (2018) · AIDS Patient Care and STDs · doi:10.1089/apc.2018.0052 · Cited by 39
The Effect of Switching from Tenofovir Disoproxil Fumarate (TDF) to Tenofovir Alafenamide (TAF) on Liver Enzymes, Glucose, and Lipid Profile
Squillace, N., Ricci, E. D., Menzaghi, B., Socio, G. V. D., Passerini, S., Martinelli, C. V., Mameli, M. S., Maggi, P., Falasca, K., Cordier, L., et al. (2020) · Drug Design Development and Therapy · doi:10.2147/dddt.s274307 · Cited by 39
Incidence of Diabetes Mellitus and Obesity and the Overlap of Comorbidities in HIV+ Hispanics Initiating Antiretroviral Therapy
Gomes, A., Reyes, E. V., Garduño, L. S., Rojas-Fermin, R. A., Mesejo, G. M., Rosario, E. D., José, L., Javier, C., Vaughan, C., Donastorg, Y., et al. (2016) · PLoS ONE · doi:10.1371/journal.pone.0160797 · Cited by 38
Cardiovascular disease in women living with HIV: A narrative review
Solomon, D., Sabin, C. A., Mallon, P. W. G., Winston, A., & Tariq, S. (2017) · Maturitas · doi:10.1016/j.maturitas.2017.11.012 · Cited by 38
Self-citation
Cardiovascular Risk Assessment in People Living With HIV: A Systematic Review and Meta-Analysis of Real-Life Data
Grand, M., Bia, D., & Díaz, A. (2019) · Current HIV Research · doi:10.2174/1570162x17666191212091618 · Cited by 41
Management of dyslipidemia in HIV-infected patients
Sugden, M. C., & Holness, M. J. (2011) · Clinical Lipidology · doi:10.2217/clp.11.25 · Cited by 39

Authors: Friis-Møller, N., Thiébaut, R., Reiss, P., Weber, R., D'Arminio Monforte, A., De Wit, S., El-Sadr, W., Fontas, E., Worm, S., Kirk, O., Phillips, A., Sabin, C. A., Lundgren, J. D., Law, M. G., & DAD study group
Affiliations: Copenhagen HIV Programme (CHIP), University of Copenhagen/Faculty of Health Science, Copenhagen, Denmark
Inserm (FR)
Amsterdam UMC Location University of Amsterdam (NL)
University Hospital Zurich (CH)
ICONA, Hospital San Paolo, University of Milan, Italy
Saint-Pierre Cohort, CHU Saint-Pierre Hospital, Brussels, Belgium
Columbia University Irving Medical Center (US)
Nice Cohort, CHU Nice Hopital de l'Archet, Nice, France
University of Copenhagen (DK)
The Royal Free Hospital (GB)
AHOD, National Centre in HIV Epidemiology and Clinical Research, Sydney, Australia
ORCID: Thiébaut, Rodolphe
Reiss, Peter
Weber, Rainer
El-Sadr, Wafaa
Kirk, Ole
Phillips, Andrew
Sabin, Caroline A.
Lundgren, Jens D.
Law, Matthew G.
Venue: European Journal of Cardiovascular Prevention & Rehabilitation
Publisher: Oxford University Press (OUP)
Published: 2010-10
Volume: 17
Issue: 5
Pages: 491-501
ISSN: 1741-8267 (ISSN-L)
DOI: 10.1097/hjr.0b013e328336a150
OpenAlex: W2160970334
Cited by: 384
References: 43
Citations by year: 2026: 6 · 2025: 11 · 2024: 13 · 2023: 12 · 2022: 16 · 2021: 28 · 2020: 23 · 2019: 25 · 2018: 16 · 2017: 38 · 2016: 36 · 2015: 43 · 2014: 24 · 2013: 33 · 2012: 34
FWCI: 28.09
Type: journal article
Language: en
Open access: green
doi.org
Licence: journals.sagepub.com/page/policies/text-and-data-mining-license (tdm)
Locations: European Journal of Cardiovascular Prevention & Rehabilitation (publishedVersion)
PubMed (publishedVersion)
University of Groningen research database (University of Groningen / Centre for Information Technology) (publishedVersion)
Zurich Open Repository and Archive (University of Zurich) (acceptedVersion)
Murdoch University Research Portal (submittedVersion)
Data Archiving and Networked Services (DANS) (submittedVersion)
Leiden Repository (Leiden University) (submittedVersion)
Ghent University Academic Bibliography (Ghent University) (submittedVersion)
Cineca Institutional Research Information System (Tor Vergata University) (submittedVersion)
Dépôt institutionnel de l'Université libre de Bruxelles (Université Libre de Bruxelles) (submittedVersion)
UCL Discovery (University College London) (submittedVersion)
Figshare (submittedVersion)
Research Portal (King's College London) (submittedVersion)
Pure Amsterdam UMC (submittedVersion)
Research at the University of Copenhagen (University of Copenhagen) (submittedVersion)
Radboud Repository (Radboud University) (submittedVersion)
Zurich Open Repository and Archive (University of Zurich) (submittedVersion)
University of Groningen research database (University of Groningen / Centre for Information Technology) (submittedVersion)
Zurich Open Repository and Archive (University of Zurich)
Funders: National Science Foundation
Bristol-Myers Squibb
Pfizer
GlaxoSmithKline
Gilead Sciences
European Commission (BIOMED2, CT94-1637, CT97-2713, QLK2-2000-00773)
Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung
National Institutes of Health
National Institute of Allergy and Infectious Diseases (U01AI046362, U01AI042170, U01AI069907)
Cilag
Topics: Health Sciences › Medicine › Infectious Diseases › HIV-related health complications and treatments
Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
Health Sciences › Medicine › Infectious Diseases › HIV/AIDS Research and Interventions
Keywords: cardiovascular risk prediction, HIV infection, antiretroviral therapy, highly active antiretroviral therapy, metabolic complications, myocardial infarction, coronary artery disease, indinavir, lopinavir/ritonavir, abacavir, Framingham risk score, cardiovascular risk factors
MeSH terms: Adult, Argentina, Australia, Coronary Disease, Drug Therapy, Combination, Europe, Female, Humans, Male, Middle Aged, Myocardial Infarction, Prospective Studies, Risk Factors, Time Factors, Reproducibility of Results, Models, Statistical, HIV Infections, Treatment Outcome, Risk Assessment, Anti-HIV Agents

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Predicting the risk of cardiovascular disease in HIV-infected patients: the Data collection on Adverse Effects of Anti-HIV Drugs Study

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks